We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
SandRidge Energy
SD
$500M
| $213K | ﹤0.01% |
50,129
-1,034
| -2% | -$4.32K |
|
2727
Uranium Energy
UEC
$5.2B
| $213K | ﹤0.01% |
231,597
-514
| -0.2% | -$498 |
|
|
AMRS
2728
DELISTED
Amyris Inc.
AMRS
| $213K | ﹤0.01% |
69,054
+14,796
| +27% | +$54.8K |
|
|
PKD
2729
DELISTED
Parker Drilling Company
PKD
| $213K | ﹤0.01% |
+9,453
| New | +$183K |
|
2730
Union Bankshares
UNB
$108M
| $212K | ﹤0.01% |
+5,838
| New | +$199K |
|
2731
Acacia Research
ACTG
$445M
| $211K | ﹤0.01% |
79,450
-361
| -0.5% | -$990 |
|
2732
Rockwell Medical
RMTI
$29.9M
| $208K | ﹤0.01% |
774
+37
| +5% | +$9.3K |
|
|
ITI
2733
DELISTED
Iteris, Inc.
ITI
| $207K | ﹤0.01% |
41,552
+2,756
| +7% | +$14K |
|
2734
ORIX
IX
$44B
| $206K | ﹤0.01% |
+12,355
| New | +$198K |
|
2735
Transmedics
TMDX
$2.79B
| $206K | ﹤0.01% |
+10,857
| New | +$199K |
|
|
NAGE
2736
Niagen Bioscience
NAGE
$276M
| $206K | ﹤0.01% |
47,884
+97
| +0.2% | +$345 |
|
|
PRTY
2737
DELISTED
Party City Holdco Inc.
PRTY
| $206K | ﹤0.01% |
88,009
-17
| -0% | -$64 |
|
2738
Clearfield
CLFD
$459M
| $205K | ﹤0.01% |
14,726
-115
| -0.8% | -$1.49K |
|
|
LEVL
2739
DELISTED
Level One Bancorp, Inc. Common Stock
LEVL
| $205K | ﹤0.01% |
+8,130
| New | +$200K |
|
2740
BlueLinx
BXC
$502M
| $204K | ﹤0.01% |
14,315
+90
| +0.6% | +$1.85K |
|
|
CASI
2741
DELISTED
CASI Pharmaceuticals
CASI
| $203K | ﹤0.01% |
6,556
+17
| +0.3% | +$551 |
|
|
UN
2742
DELISTED
Unilever NV New York Registry Shares
UN
| $203K | ﹤0.01% |
+3,534
| New | +$209K |
|
2743
OP Bancorp
OPBK
$235M
| $202K | ﹤0.01% |
19,521
-39
| -0.2% | -$384 |
|
2744
Syndax Pharmaceuticals
SNDX
$1.69B
| $202K | ﹤0.01% |
23,054
+203
| +0.9% | +$1.49K |
|
|
MR
2745
DELISTED
Montage Resources Corporation Common Stock
MR
| $202K | ﹤0.01% |
25,502
+354
| +1% | +$1.85K |
|
2746
Comstock Resources
CRK
$3.91B
| $200K | ﹤0.01% |
24,248
+4,189
| +21% | +$29.3K |
|
2747
eGain
EGAN
$200M
| $200K | ﹤0.01% |
25,308
+165
| +0.7% | +$1.28K |
|
2748
Evolus
EOLS
$403M
| $200K | ﹤0.01% |
16,448
+1,651
| +11% | +$23.3K |
|
2749
Oak Valley Bancorp
OVLY
$283M
| $200K | ﹤0.01% |
10,256
-46
| -0.4% | -$815 |
|
2750
Stagwell
STGW
$2.2B
| $200K | ﹤0.01% |
71,959
-380
| -0.5% | -$1.02K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.